Search alternatives:
changes revealed » changes related (Expand Search), images revealed (Expand Search), genes revealed (Expand Search)
larger decrease » marked decrease (Expand Search)
lower decrease » linear decrease (Expand Search), teer decrease (Expand Search), we decrease (Expand Search)
Showing 101 - 120 results of 45,889 for search '(( significantly ((lower decrease) OR (larger decrease)) ) OR ( significant changes revealed ))', query time: 1.52s Refine Results
  1. 101
    Pretreatment facial, intraoral photographs, and radiographs of the case with mandibular third molar extraction.

    Pretreatment facial, intraoral photographs, and radiographs of the case with mandibular third molar extraction. by Lijuan Liu (136685)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  2. 102
    Significantly changed USSs in the sf3b1 mutants.

    Significantly changed USSs in the sf3b1 mutants. by Bei Zhang (428038)

    Published 2021
    Save to List
    Saved in:
  3. 103
    The results of KEGG enrichment analysis (Annotation: Circles represent each pathway, and the redder the color, the larger the circle, and the more important it is).

    The results of KEGG enrichment analysis (Annotation: Circles represent each pathway, and the redder the color, the larger the circle, and the more important it is). by Lin Zhou (141050)

    Published 2023
    Save to List
    Saved in:
  4. 104
    Traits at cellular, leaf, and whole-plant scales which were significantly different [increased (↑) or decreased (↓)] or non-significant between tolerant and sensitive cultivars in the N-deficient treatment.

    Traits at cellular, leaf, and whole-plant scales which were significantly different [increased (↑) or decreased (↓)] or non-significant between tolerant and sensitive cultivars in... by Ranjeeta Adhikari (9905958)

    Published 2023
    Save to List
    Saved in:
  5. 105
    Morphological changes of skeletal muscle, fat and liver in each group.

    Morphological changes of skeletal muscle, fat and liver in each group. by Shujuan Hu (22656045)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  6. 106
    CBP per cumulative year for daratumumab and pembrolizumab per vial.

    CBP per cumulative year for daratumumab and pembrolizumab per vial. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  7. 107
    S4 Fig -

    S4 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  8. 108
    S1 Fig -

    S1 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  9. 109
    S5 Fig -

    S5 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  10. 110
    Scenario analysis for pembrolizumab using a cumulative cost-based price per year per vial.

    Scenario analysis for pembrolizumab using a cumulative cost-based price per year per vial. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  11. 111
    S3 Fig -

    S3 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  12. 112
    S6 Fig -

    S6 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  13. 113
    CBP per cumulative indication for daratumumab and pembrolizumab per vial.

    CBP per cumulative indication for daratumumab and pembrolizumab per vial. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  14. 114
    Inputs utilized in base-case and scenario analysis for daratumumab and pembrolizumab, both unadjusted and adjusted for PPP and inflation.

    Inputs utilized in base-case and scenario analysis for daratumumab and pembrolizumab, both unadjusted and adjusted for PPP and inflation. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  15. 115
    Implementation of indication-based pricing (10<sup>th</sup> scenario) for daratumumab and pembrolizumab.

    Implementation of indication-based pricing (10<sup>th</sup> scenario) for daratumumab and pembrolizumab. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  16. 116
    Scenario analysis for daratumumab using a cumulative cost-based price per year per vial.

    Scenario analysis for daratumumab using a cumulative cost-based price per year per vial. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  17. 117
    Input parameters for the base-case analysis.

    Input parameters for the base-case analysis. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  18. 118
    S2 Fig -

    S2 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  19. 119
    S1 Data -

    S1 Data - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  20. 120
    Quantitative proteome analysis of Alba3KO and AnTat 90–13 during differentiation reveals significant changes.

    Quantitative proteome analysis of Alba3KO and AnTat 90–13 during differentiation reveals significant changes. by Shubha Bevkal (10031881)

    Published 2021
    Save to List
    Saved in:

Search Tools: